Non-small cell lung cancer

• K-SAB trial Pending
  2024-515250-25-00 3 "Advanced KRASG12C-mutated non-small cell lung cancer subject"
• A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacitu … Pending
  2024-517561-16-00 4 "non-small cell lung cancer"
• Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Pending
  2024-518386-95-02 4 "Non small-cell lung cancer"
• Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations Pending
  2025-520676-26-00 4 "Non-small cell lung cancer (NSCLC)"
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 "EGFR-mutated Non-small Cell Lung Cancer"
• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors Pending
  2025-523232-39-00 1 "Advanced Solid Tumors"
• A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50% Pending
  2025-523586-18-00 5 "Non-Small Cell Lung Cancer"
• A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, a … Pending
  2025-523590-42-00 7 "Locally Advanced or Metastatic Solid Tumors"
• DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors Pending
  2025-523895-22-00 4 "Non-small cell lung cancer (NSCLC)"
• A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-s … Pending
  2025-524843-11-00 4 "Non-Small Cell Lung Cancer"
• A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC Recruiting
  2025-522867-13-00 4 2026-04-27 "Non Small Cell Lung Cancer"
• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab. Recruiting
  2025-521639-34-00 3 2026-04-20 "• Non-small cell lung cancer (Stage III, unresectable) • Sma"
• Testing HLX43 in Advanced Lung Cancer (Non-Small Cell): A Global Safety and Effectiveness Study Recruiting
  2025-523803-31-00 4 2026-04-16 "Advanced non-small cell lung cancer (NSCLC)"
• A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) Recruiting
  2025-522398-12-00 3 2026-01-30 "Locally advanced or metastatic NSCLC"
• LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and … Recruiting
  2023-508995-12-01 4 2025-12-24 "Recurrent or metastatic non-small cell lung cancer (NSCLC)"
• A clinical study to assess the efficacy of adjuvant immunotherapy with cemiplimab in patients with surgically removed non-small cell lung ca … Recruiting
  2024-519901-36-00 5 2025-12-17 "Patients with resected stage II-IIIA non-small cell lung can"
• Phase II study on the safety and feasibility of stool transplants in limited non-small cell lung cancer patients, using donors who responded … Recruiting
  2025-521251-24-00 4 2025-12-01 "Non-Small cell lung cancer (NSCLC)"
• AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors Recruiting
  2025-521707-48-00 1 2025-11-26 "KRAS Altered Advanced or Metastatic Solid Tumors"
• Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting
  2025-521775-31-00 5 2025-11-12 "Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations"
• A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C … Recruiting
  2024-517968-36-00 5 2025-07-08 "non-small cell lung cancer"
• A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on the … Recruiting
  2024-511239-91-00 4 2025-05-05 "Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)"
• A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a … Recruiting
  2023-505172-29-00 4 2025-04-24 "Resectable Non-small Cell Lung Cancer"
• A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting
  2024-514459-14-00 4 2025-04-22 "Non-Small Cell Lung Cancer"
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Recruiting
  2023-504445-31-00 4 2024-09-19 "Carcinoma, Head and Neck"

Showing 1–24 of 234 trials